Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Placebo Hepatitis Virus Infection" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Placebo Hepatitis Virus Infection for you to read. Along with our medical data and news we also list Placebo Hepatitis Virus Infection Clinical Trials, which are updated daily. BioPortfolio also has a large database of Placebo Hepatitis Virus Infection Companies for you to search.
SYNOPSIS: Prior to initiation of hepatitis C virus treatment with direct-acting antivirals, patients should be screened for hepatitis B virus coinfection. Those who are hepatitis B virus-infected should receive ongoing monitoring for flares and reactivation of hepatitis B.
The FDA will require boxed warnings on labels for certain direct-acting antiviral medications used to treat hepatitis C virus (HCV) infection following reports that the drugs reactivated hepatitis B virus (HBV) infection.
Hepatitis C virus (HCV) can cause both acute and chronic hepatitis. Most people are asymptomatic, but for the majority of patients who become infected with hepatitis C, it becomes a long-term, chronic infection. The best way to prevent hepatitis C is by avoiding behaviors that can spread the disease, especially injection drug use, as there is no vaccine for HCV. With the forefront of direct-acting...
Occult hepatitis B infection (OBI) among HIV positive patients varies widely in different geographic regions. We undertook a study to determine the prevalence of occult hepatitis B infection among HIV infected...
The US Food and Drug Administration (FDA) has approved Gilead Sciences' Vemlidy (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease.
* Initiates phase 1 clinical program of abi-h0731 for treatment of chronic hepatitis b virus infection
Few patients treated with a sofosbuvir-containing regimen for hepatitis C virus infection had late recurrent viremia, and most occurrences appeared to be reinfections.
Developed by Gilead Sciences, Vemlidy (Tenofovir Alafenamide) is indicated for the treatment of Hepatitis B virus infection with compensated liver disease in adult patients.
Janssen Research & Development has begun its Phase IIb study of combination of simeprevir, odalasvir and AL-335 to treat chronic hepatitis C virus infection without cirrhosis.
New Hampshire has made communicable disease reporting changes in the state, including the reporting of hepatitis C virus. State Health Alerts
Infection with hepatitis delta virus (HDV) in people with HIV/HBV coinfection is independently associated with higher mortality and more liver-related events, according to new findings. Reuters Health Information
Hepatitis C infection is mainly a chronic liver disease with severe complications such as decompensated cirrhosis and liver cancer. Several studies have shown that the consequences of chronic hepatitis C virus (HCV) infection are not confined to the liver but also increase the risk of cardiovascular and renal diseases and cancer.1 Most patients with chronic hepatitis C were infected before 1990, w...
Does chronic hepatitis C infection increase diabetes risk? Liver International
Ram Savan and colleagues report that two miRNAs known to suppress type 3 interferon (IFN) signaling also downregulate type 1IFN signaling in hepatitis C virus (HCV)-infected hepatocytes. The findings provide insights into the mechanisms by which antiviral IFN signaling is inhibited in HCV infection.
Vemlidy is the First New Treatment for Chronic Hepatitis B Infection to be Approved in the European Union in Nearly a Decade -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Europe...
Treatment options for patients with chronic HCV genotype 4 infections continue to expand. What are the currently available and investigative treatments for HCV GT4 infection? Journal of Viral Hepatitis
UK medical research charity MRC Technology has licensed an antibody to Newsummit Biopharma, a leading Chinese drug developer, in an effort to create a novel therapeutic for treating Hepatitis C virus (HCV) infection.
"Eiger is committed to playing a leading role in developing novel treatments for HDV infection, the most severe form of hepatitis, and building awareness of Read more...
Too many people infected with the hepatitis C virus (HCV) simply don’t know their disease status. As many as one in four cases of HCV infection are undiagnosed, as I pointed out in a blog earlier this year (Finding the Missing Cases), even when current federal guidelines for hepatitis C screening are closely followed. This …
French biopharmaceutical company ENYO Pharma is conducting its Phase I single and multiple ascending dose trial of EYP001 to treat Chronic Hepatitis B (CHB) Virus infection.
* Gilead - Japan's Ministry of Health, Labour and Welfare approves Gilead's Vemlidy for patients with chronic Hepatitis B virus infection Source text for Eikon: Further company coverage:
* European Commission grants marketing authorization for Gilead's Vemlidy (Tenofovir Alafenamide, TAF) for the treatment of chronic hepatitis B virus infection Source text for Eikon: Further company coverage:
(HealthDay)—For patients with chronic hepatitis C (CHC) treated with direct-acting antivirals (DAAs), hepatitis B virus (HBV) reactivation may occur in those with current HBV infection, according to a study published online Feb. 23 in the Journal of Gastroenterology and Hepatology.
Nov 10 (Reuters) - Gilead Sciences Inc said on Thursday the U.S. Food and Drug Administration approved its drug for patients with chronic hepatitis B virus infection.
Learning Objectives: 1. Understand the six genotypes related to hepatitis C virus (HCV). 2. List the medications and treatment options for the 6 genotypes of HCV. 3. Describe the testing for HCV and requirements for treatment. In 2015, an estimated 3.5 million people in the United States were diagnosed with the hepatitis C virus (HCV). B